Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts Details-
Title Grant Type Focus Area Country Application Due Date Real World Evidence on the Impact of Early and Appropriate Use of Aztreonam-Avibactam (ATM-AVI)Release Date:Research Inflammation & Immunology Brazil, Chile, India, Italy, South Africa, Spain, United Kingdom Guideline Concordant Care and New Data for Patients with MIBC through la/mUCEducation Oncology USA Clinical Research Studies of Atirmociclib in HR+/HER2- and/or HER2+ Breast CancerRelease Date:Research Oncology Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Korea, Mexico, Spain, Taiwan, USA, United Kingdom Quality Improvement Interventions to Enhance the Care of Patients Infected by MBL-CRE or S. maltophiliaRelease Date:Quality Improvement Inflammation & Immunology Australia, Chile, India, Italy, Spain, United Kingdom Advancing Real-World Evidence in Idiopathic Inflammatory Myopathies Through a German Disease RegistryRelease Date:Research Inflammation & Immunology Germany Real-World Evidence on Clinical Outcomes with ATM-AVI in Adult Patients with Stenotrophomonas maltophilia InfectionsRelease Date:Research Inflammation & Immunology China Real-World Evidence on Clinical Outcomes with Aztreonam-Avibactam (ATM-AVI) in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Tissue Penetration and Correlation with Clinical Outcomes of ATM-AVI in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Advancing Multidisciplinary Care in HemophiliaRelease Date:Quality Improvement Rare Disease China BCMA BsAb Educational Initiatives in 2L+ Relapsed/Refractory Multiple MyelomaRelease Date:Education Oncology USA -
Title Grant Type Focus Area Country Application Due Date Enzalutamide in the Treatment of Prostate CancerRelease Date:Partner: National Comprehensive Cancer Network, AstellasResearch Oncology USA Education of Healthcare Professionals to Provide Appropriate Medical Care for Patients with Atopic DermatitisRelease Date:Education Inflammation & Immunology Japan Addressing Primary Immunodeficiencies within Minority/Underserved PopulationsRelease Date:Education Hospital USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research – U.S.Release Date:Research Rare Disease USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Nurse Navigator Competitive Grant ProgramRelease Date:Quality Improvement Rare Disease USA Patient and Caregiver Awareness of Drug Resistant Infections (United States and Europe)Release Date:Education Hospital All Establishment of Hospital-Clinic Collaboration Model for Undiagnosed Rheumatic DiseasesRelease Date:Partner: The Japan College of RheumatologyQuality Improvement Inflammation & Immunology Japan A Quality Improvement Grant Request for Proposals Addressing Social Health Needs in Chronic and Preventative DiseaseQuality Improvement Internal Medicine USA Establishment of Support System for Healthy Life Extension of Patients with CV diseaseRelease Date:Quality Improvement Internal Medicine Japan Racial and Ethnic Disparities in the Menopause ExperienceRelease Date:Education Internal Medicine USA Immunotherapy in Urothelial CarcinomaRelease Date:Partner: Merck KGaA Darmstadt, Germany and EMD SeronoEducation Oncology All Managment of Metabolic Risks that Drive Liver Diseases and Increase Cardiovascular Risk in NASHRelease Date:Education Internal Medicine All